In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CSL to acquire Aventis Behring for up to €760.5mm

Executive Summary

Australian drug company CSL has signed an agreement to acquire Aventis Behring (the therapeutic protein unit of Aventis SA) for up to €760.5mm ($925mm). CSL will merge the business with its ZLB Bioplasma business and name the combined company ZLB Behring.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash

Related Companies